ClinicalTrials.gg
RecruitingNCT07295262Updated Dec 19, 2025

NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

An Early Phase 1 interventional study of ICG-Cisplatin Nanoprobe (NIR-II NanoM) and Fluorescence-guided Hepatectomy in Liver Cancer, Adult, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by West China Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Hepatocellular by West China Hospital — 15 open to participants now, 15 under way, none of them phase 3. Carcinoma, Hepatocellular · West China Hospital.

Planned enrollment
8th of 14
30 · median 32
Started
2026
with 6 others
Phase 1
6 of 18
5 open now
Primary completion
2028-07
later than 11 of 14 live
Registered
11th of 18
by date

Among the 18 studies in Carcinoma, Hepatocellular by West China Hospital, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 7 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 11 of the 14 other live ones, and was the 11th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

15 of the 18 studies in Carcinoma, Hepatocellular by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Hepatocellular by West China Hospital, or all of them as a file.
02

Study summary

This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.

03

Conditions studied

  • Liver Cancer, Adult

Keywords

  • liver cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years.
  2. First diagnosis of Hepatocellular Carcinoma (HCC) (non-recurrent).
  3. Single tumor with diameter ≤ 5 cm.
  4. Assessed as resectable by more than 2 senior liver surgeons (experience >10 years, >500 hepatectomies).
  5. No distant on preoperative chest CT and abdominal contrast-enhanced CT.
  6. Class A liver function.
  7. Patient or legal guardian able to understand the study and sign .

Exclusion criteria

Exclusion Criteria:

  1. Postoperative pathology confirms cholangiocarcinoma, sarcomatoid HCC, combined HCC-ICC, or fibrolamellar carcinoma.
  2. Presence of portal vein, hepatic vein, or bile duct tumor thrombus.
  3. History of other (except cured carcinoma in situ of cervix, basal cell carcinoma, or squamous cell skin carcinoma).
  4. Evidence of residual lesion, recurrence, or during preoperative assessment; or postoperative pathology confirming lymph node metastasis or positive margins.
  5. Moderate to severe ascites requiring therapeutic paracentesis/drainage, or score > 7 (except for small amount of ascites on imaging without clinical symptoms).
  6. Uncontrolled or moderate/large amount of pleural effusion or pericardial effusion.
  7. Severe cardiac, pulmonary, or renal dysfunction.
  8. Ruptured HCC requiring emergency surgery.
  9. Patient or family unable to understand the study conditions and objectives.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental: NIR-II NanoM Group

    Patients receive transarterial embolization (TAE) with ICG-Cisplatin self-assembled nanoprobes (NIR-II NanoM) mixed with lipiodol, followed by fluorescence-guided laparoscopic anatomic hepatectomy.

    Drug: ICG-Cisplatin Nanoprobe (NIR-II NanoM) · Procedure: Fluorescence-guided Hepatectomy

Interventions

  • DrugICG-Cisplatin Nanoprobe (NIR-II NanoM)

    Self-assembled nanoprobes of Indocyanine Green (ICG) and Cisplatin mixed with lipiodol (Shift\&NanICG), administered via superselective transarterial injection for tumor staining.

  • ProcedureFluorescence-guided Hepatectomy

    Laparoscopic anatomic hepatectomy guided by Near-Infrared II (NIR-II) fluorescence imaging system to visualize tumor boundaries.

06

What researchers measure

Primary outcomes

  1. 3-Year Recurrence-Free Survival (RFS)

    Calculated from the date of surgery to the date of first documented recurrence (local or distant) or death from any cause.

    Time frame: Up to 3 years post-surgery

  2. Rate of Successful Fluorescence Staining

    The proportion of participants with successful visualization of the tumor. Success is defined as the NIR-II nanoprobe showing clear fluorescence signals in the tumor tissue under the NIR-II imaging system during surgery, enabling the surgeon to distinguish tumor boundaries and liver segments for precise resection.

    Time frame: Intraoperative (Day 0)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time interval from the date of surgical resection to the date of death from any cause. For participants who are lost to follow-up, the last known contact date will be used as the censorship time.

    Time frame: From date of surgery up to 3-5 years

  2. Incidence of Perioperative Adverse Events and Complications

    The number of participants experiencing adverse events related to the nanoprobe (e.g., allergic reactions, nephrotoxicity) or surgical complications (e.g., bleeding, infection, bile leakage, liver failure). Events will be monitored and recorded according to standard clinical practice.

    Time frame: From enrollment through 30 days post-surgery

  3. Rate of Local Recurrence

    The percentage of participants who develop tumor recurrence specifically in the original surgical area (resection margin or tumor bed), with or without an elevation in tumor markers.

    Time frame: From date of surgery up to 3 years

  4. Rate of Distant Metastasis

    The percentage of participants with metastasis detected in distant organs (e.g., lung, bone) or other liver segments. Metastasis is confirmed by CT, MRI, or nuclear scan without the mandatory need for pathological biopsy.

    Time frame: From date of surgery up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jul 2028, 30 months later.

Of 147 non-industry phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 80. This study's planned 30 months is below that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 19, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07295262
Responsible party
Jiwei Huang (Clinical Professor, West China Hospital) — Principal investigator
First posted
Dec 19, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Dec 19, 2025

Study contacts

Jiwei Huang Professor
Contact
huangjiwei@wchscu.cn
18980606725

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion